Clinical characteristics and outcomes of patients with bacteraemia caused by non-carbapenemase-producing, carbapenem-resistant Enterobacterales
Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)
DOI: 10.1093/jac/dkag267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 06.08.2026. Verfasst von Sunish Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Antibiotic Management Program, University of Pittsburgh Medical Center, Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA …. Hauptthemen laut MEDLINE: Bacteremia, Anti-Bacterial Agents, Carbapenem-Resistant Enterobacteriaceae, Enterobacteriaceae Infections. Die Arbeit nennt 16 Literaturangaben. Gefördert von: University of Pittsburgh Medical Center.
Abstract (Originalsprache)
Objectives
Carbapenem-resistant Enterobacterales (CRE) are classified as carbapenemase- and non-carbapenemase-producing (non-CP) CRE. The purpose of this study was to identify factors associated with meropenem non-susceptible non-CP CRE to help stratify treatment approaches and to report rates of treatment-emergent resistance among patients with non-CP CRE bacteraemia.
Methods
This was a retrospective, single-centre study of patients hospitalized between January 2015 and September 2025 with bacteraemia due to Enterobacterales resistant to ertapenem and confirmed to be non-CP. Ertapenem resistance was determined by broth microdilution susceptibility testing. Carbapenemase testing was performed by modified carbapenem-inactivation method, polymerase chain reaction or whole-genome sequencing.
Results
Among 60 patients who met the inclusion criteria, the median (IQR) age was 63 years (57–73), 33% (20/60) were female and 18% (11/60) were organ transplant recipients. Patients infected with meropenem non-susceptible non-CP CRE were more likely to have prior meropenem exposure [60% (10/15) versus 13% (8/45), P < 0.001] and have breakthrough bacteraemia [60% (9/15) versus 29% (13/45), P = 0.031]. Treatment-emergent resistance developed in 16% (4/24) and 0% (0/15) of patients treated with meropenem and ceftazidime-avibactam, respectively.
Conclusions
These exploratory data provide new insights into clinical factors associated with meropenem non-susceptible non-CP CRE and support future investigations into the comparative-effectiveness of meropenem versus beta-lactam/beta-lactamase inhibitors for the treatment of meropenem-susceptible non-CP CRE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Antibiotic Management Program, University of Pittsburgh Medical Center, Falk Medical Building, Suite 3A, Room 317, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA.
- Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
ORCID-Profile: Sunish Shah, Ellen G Kline, Ryan K Shields
Förderung
- University of Pittsburgh Medical Center
Zitieren
APA
Shah, S., Clarke, L. G., Kline, E. G., Marini, R. V., Squires, K. M., & Shields, R. K. (2026). Clinical characteristics and outcomes of patients with bacteraemia caused by non-carbapenemase-producing, carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag267
Vancouver
Shah S, Clarke LG, Kline EG, Marini RV, Squires KM, Shields RK. Clinical characteristics and outcomes of patients with bacteraemia caused by non-carbapenemase-producing, carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag267
BibTeX
@article{Shah2026,
author = {Shah, Sunish and Clarke, Lloyd G and Kline, Ellen G and Marini, Rachel V and Squires, Kevin M and Shields, Ryan K},
title = {Clinical characteristics and outcomes of patients with bacteraemia caused by non-carbapenemase-producing, carbapenem-resistant Enterobacterales},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {9},
doi = {10.1093/jac/dkag267}
}
EUVIMED